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http://dx.doi.org/10.1016/j.fjs.2013.Summary Hepatoblastoma (HB) is the most common malignant tumor of the liver in children
in countries where hepatitis B is not endemic, and this has also been the case in Taiwan since
nationwide hepatitis B vaccinations were implemented in 1984. The outcome of HB has
become much better in the past two decades because of improved imaging modalities, adju-
vant and neoadjuvant chemotherapy, and technical improvements in liver resection and liver
transplantation. In this mini-review, the current strategy of HB treatment as reported in the
literature will be described.
Copyright ª 2013, Taiwan Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Hepatoblastoma (HB) is the most common malignant liver
tumor in children, with an incidence of 0.7 to 1 per million
children under 15 years of age in Western countries.1 In
Taiwan, the incidence of HB is higher than that of hepa-
tocellular carcinoma, and it has become the most common
malignant tumor in children in the past two decades after
nationwide hepatitis B vaccinations were implemented in
1984.2ediatric Surgery, Division of
of Surgery, Taipei Veterans
Shih-Pai Road, Taipei 112,
w (C.-S. Liu).
ight ª 2013, Taiwan Surgical Asso
04.004Although the outcome of HB was poor three decades
ago, the long-term survival rates today have improved,
reaching 75e80%, largely because of advances in chemo-
therapy and better surgical decision-making.3 However,
whereas complete surgical resection remains the most
important intervention required to achieve long-term cure,
tumors are resectable when they are diagnosed in only 60%
of patients that present with tumors.4 For those patients
with initially unresectable tumors, adjuvant chemotherapy
and liver transplantation have expanded the scope of
treatment alternatives to achieve the goal of curative
therapy.5
2. Epidemiology and incidence
HB is the most common hepatic malignancy in children,
accounting for nearly 80% of all malignant liver tumors, andciation. Published by Elsevier Taiwan LLC. All rights reserved.
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with an abdominal mass, failure to thrive, and anemia.6
Boys are affected more commonly than girls, with a mal-
e:female ratio ranging from 1.2:1 to 3.6:1.7 In one study,
the mean age at diagnosis was 19 months, and the median
age was 16 months.8
3. Histology
HB is mainly divided into two histologic types: epithelial,
accounting for 56% of cases, and mixed epithelial/mesen-
chymal.9 The epithelial type can be further divided into fetal
(31%), embryonal (19%), macrotrabecular (3%), and small-
cell undifferentiated subtypes (3%).10 It has been observed
that the subtypes have an effect on the prognosis, with the
pure fetal type having the most favorable outcome and the
small-cell undifferentiated type having the worst.11,12
4. Associated risk factors
Although most cases of HB are sporadic without any
associated anomalies, some associated risk factors have
been reported, such as parental smoking,13 Beckwithe
Wiedemann syndrome,1 familial adenomatous polyposis,14
and low birthweight.15 In our own experience, twins seem
to have a higher incidence of HB in one of the twins than in
the other (not yet reported).
5. Clinical picture
Patients with HB often present with an asymptomatic
abdominal bulging mass found incidentally. Anorexia,
weight loss, abdominal pain, and emesis are other pre-
senting symptoms that indicate more advanced disease.
The right lobe of the liver is affected more commonly than
the left, and in 35% of patients there is bilateral involve-
ment.16 Around 20% of patients present with metastasis,
most in the lung at the time of diagnosis.
Laboratory findings typically show a mild elevation of
liver enzymes. Very high levels of serum alpha-fetoprotein
(AFP) are noted in over 90% of patients, the level often
being higher than 1105 mg/l. AFP is an excellent tumor
marker that not only reflects the extent of the disease, but
also is very useful for monitoring both the effect of ongoing
therapy and tumor recurrence at an early stage.16
6. Staging
Two staging systems are commonly used. A decision to use
the old system (the Children’s Cancer Group or Pediatric
Oncology Group system) is based on the findings at surgery or
after surgery, and thus greatly depends on the surgeon’s
surgical technique. In this system, Stage I refers to complete
resection with negative margins, Stage II to gross resection
with microscopically positive margins, Stage III to gross re-
sidual disease after attempted resection or biopsy only, and
rupture of the capsule, and Stage IV to distant metastasis.
The other system is the PRETEXT (Pretreatment Exten-
sion) system, designed by the International Childhood Liver
Tumor Strategy Group (SIOPEL)17,18 and with goodinterobserver reproducibility and good prognostic value.
The PRETEXT system has been made more accurate by
advanced imaging facilities such as computed tomographic
angiography and magnetic resonance imaging. This system
has been evolving for 20 years, and the updated PRETEXT
staging is described in the 2005 report.18
The PRETEXT staging system is based on Couinaud’s
system of segmentation of the liver,19 which groups the liver
into four sections: Segments 2 and 3 (left lateral section),
Segments 4a and 4b (left medial section), Segments 5 and 8
(right anterior section), and Segments 6 and 7 (right poste-
rior section). The term “section” is used here (where other
authors use “segment” or “sector”) to avoid terminologic
confusion. In the original system, the caudate lobe (Segment
1) was ignored. Determination of the PRETEXT stage takes
into consideration the involved sections not only prior to,
but also after resection. For example, if the tumor involves
only the left medial section, the PRETEXT is Stage II rather
than Stage I because hepatectomy will also resect the left
lateral section. This number roughly estimates the difficulty
of the surgical resection.
In addition to describing the intrahepatic extent of the
primary tumor(s), the PRETEXT system includes “additional
criteria” that assess the involvement of the inferior vena
cava or hepatic veins (designated V), the portal vein (P),
extrahepatic abdominal disease (E), and distant metastases
(M). The purpose of these criteria, although confusing, was
to clarify the criteria for “extrahepatic” disease and to
improve our ability to identify prognostic imaging findings
and refine risk stratification. Therefore, the original SIOPEL
risk stratification system for HB has been modified in the
protocols for current SIOPEL studies.7. Treatment
Although complete surgical resection provides the best
outcome and is the ultimate goal of therapy, the addition of
chemotherapy has changed treatment from surgery alone
to a multimodal approach. Chemotherapy alone, and later
with a good surgical technique, has improved survival in
patients who in the past had unresectable or metastatic
disease by reducing the tumor size and permitting complete
tumor resection or transplantation. Our own data (part of
the data published)2 showed that the 3-year survival rate
for HB increased from zero to 55% and 91% for the periods
1978e1990, 1991e2001, and 2002e2010, respectively.
Chemotherapy is effective as both an adjuvant and a
neoadjuvant treatment by separating the tumor from the
surrounding vascular structure and thus decreasing the rate
of incomplete tumor resection. Cisplastin, vincristine, 5-
fluorouracil, cyclophosphamide, and doxorubicin are among
the most useful chemotherapeutic agents.
The recommended algorithm in the management of HB,
utilizing a combination of conventional resection, chemo-
therapy, and transplantation proposed by Tiao et al.5
However, there are several questionable points in this al-
gorithm. First, what is the definition of a so-called resect-
able tumor? Second, is getting tissue proof necessary for an
unresectable tumor before chemotherapy? Third, is
chemotherapy better for difficult but resectable tumors
before resection? Fourth, should more cycles of
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sectable after four cycles of chemotherapy? Last, is it
necessary to give two more cycles of chemotherapy after
liver transplantation?
As to the first controversial point, PRETEXT Stage I tu-
mors are resectable for most surgeons, but resection of
Stage II is dependent on the surgeon’s ability. A unifocal,
centrally located tumor in Stage II involving the main hilar
structures should be considered unresectable. For Stage III/
IV disease, chemotherapy is always recommended prior to
any trial of resection. Although complete resection is still
possible after chemotherapy if the tumor remains in Stage
III/IV,20 this depends on the surgeon’s ability, and liver
transplantation is recommended for an unresectable Stage
III/IV tumor21 because the outcome of rescue liver trans-
plantation is poor.
As regards the second point, although obtaining tissue
proof prior to chemotherapy via either a percutaneous
route or an open method is safe, it is not always necessary.
Patients with a low AFP level, or older children in partic-
ular, who are hepatitis B carriers, should have tissue proof
prior to chemotherapy.
As for the third point, although some surgeons favor
chemotherapy prior to resection even if the tumor is resect-
able,22 our personal experience leads us to prefer Tiao et al’s
protocol,5 although resectability should be very clear. Heroic
attempts at partial hepatectomy are discouraged because
chemotherapy is effective for downstaging most HBs.
For the fourth point, we prefer two more cycles of
chemotherapy for any tumor with equivocal resectability
prior to making a decision for resection or liver trans-
plantation if the tumor is susceptible to chemotherapy, as
manifested by decreasing AFP levels or a reduction in tumor
size. Of course, we should keep the possibility of chemo-
resistance of tumor in mind when dealing with such cases.
For the final point, most transplant surgeons prefer
post-transplant chemotherapy,23 and, in general, this has
been tolerated well in most post-transplant patients,5
although the benefit has not yet been proven, and post-
transplant chemotherapy should be tailored to the indi-
vidual child.
Persistence of viable extrahepatic deposits after
chemotherapy that are not amenable to surgical resection
is the only absolute contraindication for liver trans-
plantation. Macroscopic venous invasion (portal vein, he-
patic vein, and vena cava) is not a contraindication if en
bloc complete resection can be performed. Patients with
incomplete tumor resection after partial hepatectomy or
intrahepatic relapse can have so-called rescue liver trans-
plantation, but the survival rate is much lower than in
primary liver transplantation.5 Patients with lung metas-
tasis at presentation should not be excluded from liver
transplantation if it clears completely after chemotherapy.
Complete eradication of metastatic lesions by chemo-
therapy and surgical resection of any suspicious remnant is
a paramount prerequisite for transplantation.21,24,25
In conclusion, excellent results of HB treatment have
been achieved in recent decades by a combination of
chemotherapy, radical tumor resection, and liver trans-
plantation. In cases without distant metastasis, an overall
5-year survival is more than 90% with PRETEXT Stages I and
II, meanwhile with POSTTEXT (post-chemotherapy) StagesI/II and III without liver transplantation, the overall 5-year
survival rate reaches 90% and 75%, respectively. In cases
with POSTTEXT III and IV without distant metastasis, liver
transplantation should be seriously considered prior to an
attempt at liver resection because primary liver trans-
plantation can offer a far better survival than rescue liver
transplantation.References
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